TRANSREG has been launched.

​TRANSREG ​​is a multicenter, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose IL2 across 11 selected autoimmune diseases (12 patients/disease) including heumatoid arthritis, ankylosing spondylitis, systemic lupus erythematous, psoriasis, Behçet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, and sclerosing cholangitis. 

Please click here for further information.​​